pipette
ENEnglish

Characterization of the Preclinical in Vitro and in Vivo Pharmacokinetic Properties of the Cyclic Oligomeric Depsipeptide Ryanodine Receptor 2 Inhibitor ent-Verticilide

T. Q. Do, R. D. Crouch, K. Wu, M. P. Thorpe, A. N. Smith, J. N. Johnston, W. S. Akers, B. C. Knollmann

Preprint

En palabras de los autores

ent-Verticilide is a synthetic cyclic oligomeric depsipeptide that inhibits ryanodine receptor 2 (RyR2)-mediated calcium (Ca) leak and has demonstrated antiarrhythmic activity in mice. This study characterized the preclinical absorption, distribution, metabolism, and pharmacokinetic properties of ent-verticilide and investigated factors affecting its oral exposure. ent-Verticilide was stable in rat plasma and simulated gastric and intestinal fluids but exhibited extensive plasma protein binding (>94%) and low apparent permeability in Caco-2 cells, with no evidence of pronounced net efflux. In rat and human liver microsomes, ent-verticilide underwent rapid NADPH-dependent metabolism, with an in vitro half-life of 5.43 min and 4.35 min, respectively, and a predicted hepatic extraction ratio of 0.90 and 0.92, respectively. Following intravenous administration in rats, ent-verticilide exhibited a systemic clearance of 25.5 mL/min/kg and a large steady-state volume of distribution (4.72 L/kg). Absolute oral bioavailability was approximately 16%. Simultaneous portal and systemic sampling estimated intestinal availability (FaFg) at 0.25 and hepatic availability (Fh) at 0.64, suggesting that processes occurring before hepatic entry are a major limitation to oral exposure. Pretreatment with the CYP inhibitor 1-aminobenzotriazole increased portal and systemic exposure approximately 10.6- and 18.5-fold, respectively, and increased apparent Fh to approximately 1. Collectively, these findings identify limited intestinal availability and CYP-mediated presystemic metabolism as important determinants of ent-verticilide exposure and provide a framework for its continued development as an RyR2-targeted therapeutic.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 28 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.26.761690